Biomol Ther  
Oncogene-Driven Metabolic Alterations in Cancer
Hye-Young Min1,2 and Ho-Young Lee1,2,3,*
1Creative Research Initiative Center for concurrent control of emphysema and lung cancer, College of Pharmacy, Seoul National University, 2Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Pharmacy, Seoul National University, 3College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea
E-mail: hylee135@snu.ac.kr
Tel: +82-2-880-9277, Fax: +82-2-6280-5327
Received: October 18, 2017; Revised: October 25, 2017; Accepted: October 27, 2017; Published online: December 7, 2017.
© The Korean Society of Applied Pharmacology. All rights reserved.

Abstract
Cancer is the leading cause of human deaths worldwide. Understanding the biology underlying the evolution of cancer is important for reducing the economic and social burden of cancer. In addition to genetic aberrations, recent studies demonstrate metabolic rewiring, such as aerobic glycolysis, glutamine dependency, accumulation of intermediates of glycolysis, and upregulation of lipid and amino acid synthesis, in several types of cancer to support their high demands on nutrients for building blocks and energy production. Moreover, oncogenic mutations are known to be associated with metabolic reprogramming in cancer, and these overall changes collectively influence tumor-microenvironment interactions and cancer progression. Accordingly, several agents targeting metabolic alterations in cancer have been extensively evaluated in preclinical and clinical settings. Additionally, metabolic reprogramming is considered a novel target to control cancers harboring un-targetable oncogenic alterations such as KRAS. Focusing on lung cancer, here, we highlight recent findings regarding metabolic rewiring in cancer, its association with oncogenic alterations, and therapeutic strategies to control deregulated metabolism in cancer.
Keywords: Cancer, Non-small cell lung cancer, Cancer metabolism, Metabolic reprogramming, Aerobic glycolysis, Oncogenic alteration


This Article

e-submission

Archives